account_id none on file
legal_name Teva Pharmaceutical Industries Ltd
ticker TEVA
cik 818686
domain tevapharm.com
linkedin_company_url https://www.linkedin.com/company/teva-pharmaceuticals/
entry_point_account_id none on file
name Teva Pharmaceutical Industries Limited
exchange NYSE
sector Health Care
hq Tel Aviv, Israel
sector index/company/sector/health-care/
calls 1 filings 0 executives 2 family 0
why_nownone on file
calls
This quarter of 2024 were 3.8 billion, an increase of 4% in U.S. dollars and 5% in local currency terms compared to the first quarter of 2023, the increase was mainly driven by broad-based growth from generics products across all our segments globally, including strong contribution from generics travel made in the U.S., continued strong growth in Ocedo as well as the Jovi in our Europe and international market segments.
May 8, 2024 / receipt, needs a key / Eli Khalif, CFO | earnings call 2024-05-08 | transcript a650ec48-33e0-4175-a167-672c368e12e0 | chars 17746-18169 | segment 18
filingsnone on file
executives
| Eli Khalif | CFO | - | receipt |
| Richard Francis | CEO | - | receipt |
familynone on file
upcoming
changesnone on file
mcp_package_hint
slug teva-pharmaceutical-industries-limited
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$